The newly amended Medical Psilocybin Act would create a state supervised program granting psilocybin access — including take-home use for some — to patients with qualifying conditions.

We’re building the case that psilocybin therapy stands to deliver better outcomes, at a lower long-term cost, than many of the existing mental health programs and treatments states are spending tens of billions of dollars on.

Industry insiders weigh in on the growing pains of Oregon's regulated psilocybin program which has seen concerns raised about licensing fees and some service centers close.

Oregon Health & Science University has been awarded a $3.3 million grant from the National Institute on Drug Abuse to study outcomes from legal, state-regulated psilocybin services in real-world community settings.

Misleading headlines around New Jersey’s psilocybin pilot program reveal how misinformation and weak media literacy are distorting psychedelic policy debates nationwide.

Without deliberate policy solutions, state-based programs risk remaining narrow, unaffordable, and politically fragile. But if we can solve for affordability, the implications extend far beyond psychedelics.

Over the coming months, we will be sharing a short series on Oregon’s lessons, national trends, and how states can build the first wave of affordable, state-funded access programs that meet people where they are.

At Psychedelic Science 2025, Center for Psychedelic Policy founder Sam Chapman outlined how pilot programs and creative funding mechanisms can realize state-funded, legal psychedelic access for those who stand to benefit the most.